First Bank & Trust bought a new position in Astrazeneca PLC (NYSE:AZN) during the fourth quarter, Holdings Channel reports. The institutional investor bought 23,498 shares of the company’s stock, valued at approximately $642,000.
Several other hedge funds also recently modified their holdings of the company. ETRADE Capital Management LLC increased its stake in shares of Astrazeneca PLC by 216.9% in the third quarter. ETRADE Capital Management LLC now owns 66,941 shares of the company’s stock worth $2,200,000 after buying an additional 45,820 shares during the period. D.A. Davidson & CO. increased its stake in shares of Astrazeneca PLC by 436.5% in the third quarter. D.A. Davidson & CO. now owns 23,100 shares of the company’s stock worth $757,000 after buying an additional 18,794 shares during the period. Price T Rowe Associates Inc. MD bought a new stake in shares of Astrazeneca PLC during the third quarter worth about $41,867,000. OLD Republic International Corp bought a new stake in shares of Astrazeneca PLC during the third quarter worth about $24,577,000. Finally, LPL Financial LLC bought a new stake in shares of Astrazeneca PLC during the third quarter worth about $485,000. 13.05% of the stock is owned by institutional investors and hedge funds.
Astrazeneca PLC (NYSE:AZN) traded down 2.07% on Thursday, reaching $27.91. The company’s stock had a trading volume of 3,692,976 shares. The firm’s 50 day moving average price is $27.37 and its 200-day moving average price is $30.38. The company has a market capitalization of $70.61 billion, a price-to-earnings ratio of 28.64 and a beta of 0.78. Astrazeneca PLC has a 52 week low of $25.55 and a 52 week high of $35.04.
Astrazeneca PLC (NYSE:AZN) last posted its earnings results on Thursday, November 10th. The company reported $1.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.74 by $0.58. Astrazeneca PLC had a return on equity of 31.30% and a net margin of 10.35%. The business earned $5.70 billion during the quarter, compared to analyst estimates of $5.95 billion. During the same quarter last year, the firm earned $1.03 earnings per share. The company’s revenue for the quarter was down 2.6% compared to the same quarter last year. On average, equities analysts predict that Astrazeneca PLC will post $2.07 EPS for the current year.
A number of analysts have issued reports on the company. Zacks Investment Research raised Astrazeneca PLC from a “sell” rating to a “hold” rating in a research note on Monday. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Astrazeneca PLC in a research report on Tuesday, December 13th. Leerink Swann raised Astrazeneca PLC from a “market perform” rating to an “outperform” rating and set a $34.00 price objective for the company in a research report on Friday, December 9th. Liberum Capital raised Astrazeneca PLC from a “hold” rating to a “buy” rating in a research report on Friday, November 25th. Finally, Deutsche Bank AG reissued a “buy” rating on shares of Astrazeneca PLC in a research report on Friday, November 11th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $37.27.
Astrazeneca PLC Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca PLC (NYSE:AZN).